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The History of Long-QT Syndrome and Brugada SyndromeOfer Havakuk, MD, Sami Viskin, MDABSTRACTFro
ha
MaThe Brugada syndrome (BrS) and long-QT syndrome (LQTS) present as congenital or acquired disorders with diagnostic
electrocardiograms (ST-segment elevation and prolonged QT interval, respectively) and increased risk for malignant
arrhythmias. Our understanding of the 2 disease forms (congenital vs. acquired) differs. A female patient on quinidine for
atrial ﬁbrillation who develops ventricular ﬁbrillation is diagnosed with “acquired LQTS” and is discharged with no
therapy other than instructions to avoid QT-prolonging medications. In contrast, an asymptomatic male patient who
develops a Brugada electrocardiogram on ﬂecainide is diagnosed with “asymptomatic BrS” and could be referred for an
electrophysiological evaluation that could result in deﬁbrillator implantation. The typical patient undergoing deﬁbrillator
implantation for BrS is asymptomatic but has a Brugada electrocardiogram provoked by a drug. The authors describe how
the histories of LQTS and BrS went through the same stages, but in different sequences, leading to different conclusions.
(J Am Coll Cardiol 2016;67:100–8) © 2016 by the American College of Cardiology Foundation.“History is nothing whatever but a record of
what living persons have done in the past.”
—Rose Wilder Lane (1)
T his observation is exempliﬁed by thenonparallel pathways that led to differentapproaches for the management of 2 com-
mon arrhythmic syndromes: long-QT syndrome
(LQTS) and Brugada syndrome (BrS).
The 2013 Heart Rhythm Society, European Heart
Rhythm Association, and Asia Paciﬁc Heart Rhythm
Society consensus report states that congenital LQTS
(cLQTS) is diagnosed “in the presence of [corrected]
QT interval >500 ms.when a secondary cause for
QT-prolongation is absent.” In contrast, BrS is diag-
nosed “in patients with ST-segment elevation with
type 1 morphology.either spontaneously or after
provocative drug test with a Class I antiarrhythmic
drug” (2).
This fundamental discrepancy in diagnostic
approach is intriguing. After all, both LQTS and
BrS share important characteristics: both present asm the Tel Aviv Sourasky Medical Center and Sackler School of Medicine
ve reported that they have no relationships relevant to the contents of th
nuscript received July 21, 2015; revised manuscript received September 1congenital or acquired (mainly drug-induced) ar-
rhythmogenic disorders; both have diagnostic elec-
trocardiograms (ECGs), with a prolonged QT interval
in the former (Figure 1) and coved ST-segment
elevation >2 mm in the latter (Figure 2); and both
may lead to polymorphic ventricular tachyarrhyth-
mias (Figures 1 and 2). However, our understanding of
the interplay between these 2 forms (congenital and
acquired) of disease differs.
Take, for example, the following patients: 1) a
woman on quinidine for atrial ﬁbrillation who de-
velops torsades de pointes (TdP) and ventricular
ﬁbrillation (VF) requiring resuscitation; and 2) an
asymptomatic man who develops a type I Brugada
ECG after receiving intravenous ﬂecainide. After car-
diac arrest from quinidine, the female patient is likely
to receive a diagnosis of drug-induced LQTS (diLQTS)
and will be discharged with no therapy, other than
instructions to avoid QT-prolonging medications.
In contrast, the asymptomatic male patient with
ﬂecainide-induced ST-segment elevation is likely to
be diagnosed with asymptomatic BrS and could be, Tel Aviv University, Tel Aviv, Israel. Both authors
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8, 2015, accepted October 6, 2015.
AB BR E V I A T I O N S
AND ACRONYM S
BrS = Brugada syndrome
cLQTS = congenital long-QT
syndrome
diLQTS = drug-induced long-
QT syndrome
ECG = electrocardiogram
EPS = electrophysiological
study
ICD = implantable
cardioverter-deﬁbrillator
LQTS = long-QT syndrome
TdP = torsades de pointes
VF = ventricular ﬁbrillation
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101referred for an electrophysiological study (EPS) that,
if the ﬁndings are positive, will result in the implan-
tation of an implantable cardioverter-deﬁbrillator
(ICD).
We explore the possibility that the divergent
course of events during the description of these 2
diseases led to the paradigms behind their different
modes of treatment. In other words, the histories of
LQTS and BrS went through the same stages,
including: 1) description of the congenital and ac-
quired forms of each disease; 2) understanding of the
pathophysiology of each disease type; and 3) under-
standing of the interaction between the 2 disease
variants, with the eventual development of diag-
nostic tests. However, the sequence of these stages
differed for LQTS and BrS (Central Illustration).
ACT I: HISTORY OF LQTS
RECOGNITION OF THE CONGENITAL FORM OF
LQTS. The recognition that QT prolongation might be
responsible for sudden death emerged in the late
1950s, as Jervell and Lange-Nielsen (3) and Levine and
Woodworth (4) described sudden deaths in children
with congenital deafness. In the affected children,
ECGs showing prolonged QT intervals were docu-
mented, although no malignant tachyarrhythmias
were captured (3,4). Shortly thereafter, Romano et al.
(5) andWard (6) reported additional families with long
QT intervals and sudden death but without deafness.
None of the original publications included recordings
of the arrhythmias’ onset, although some in-
vestigators had them (Figure 1). Consequently, the
cause-and-effect association between QT prolonga-
tion and the risk for sudden death remained unex-
plained for years. Although Levine and Woodworth’s
(4) contribution was never acknowledged, the
Jervell-Lange-Nielsen and Romano-Ward syndromes
became recognized as cLQTS with and without deaf-
ness, respectively. It would take 40 years to explain
the deafness component of the syndrome (7). More
important, the story of an acquired form of LQTS was
developing in parallel, and it would take the same
amount of time before physicians grasped the inter-
play between the congenital and the acquired forms of
the disease.
diLQTS. In 1964, Selzer and Wray (8) documented
polymorphic ventricular tachyarrhythmia as the
cause of “quinidine syncope.” Tales of patients
treated with quinidine suddenly collapsing, some-
times even dying suddenly, had been around since
the early 1920s (9,10), but the connection between
quinidine and long QT intervals had not been recog-
nized. Instead, “systemic embolism” or “quinidineshock” from toxic effects on the nervous
system (11) were the prevailing explanations.
Dessertenne (12) not only described in detail
the same arrhythmia in patients with atrio-
ventricular block but also coined the term
eventually used to denote the unique ar-
rhythmia of LQTS: torsades de pointes.
Strange as it may sound today, neither
Dessertenne (12) nor Selzer and Wray (8)
considered QT prolongation as the cause of
TdP, instead blaming the arrhythmia on
widening of the QRS complex. The lack of
understanding of the interplay between the
drug effects, the QT prolongation, and the
arrhythmia is best illustrated by the use of
quinidine at that time to treat the arrhyth-
mias caused by congenital (3) and atrioventricular
block–related (13) LQTS. Only during the following
years was QT prolongation by quinidine linked to
arrhythmia causation (14–16).
Other drugs were soon found to display compara-
ble effects on the QT segment, with similar conse-
quences, making diLQTS a recognized entity. This
phenomenon became even more intriguing as medi-
cations with noncardiac indications (naturally as-
sumed to have no cardiac effects) were recognized to
display proarrhythmic effects. The ﬁrst was the anti-
psychotic drug thioridazine (17). Ironically, as
described earlier, quinidine was used at some point to
treat this new form of diLQTS (17). The medical
community would have to wait until the 1990s before
the mechanism of QT prolongation by noncardiac
drugs would ﬁnally be understood.
UNDERSTANDING QT PROLONGATION. The mecha-
nism responsible for QT prolongation remained
elusive for decades. The observation that syncope
and cardiac arrest in patients with cLQTS are often
triggered by stress (18) led researchers to believe that
sympathetic imbalance is responsible for the disease.
Animal experiments showing that stimulation of the
left sympathetic ganglion produced QT prolongation
(19) provided credible proof for the “sympathetic
imbalance” theory, to the point that in 1971, Moss and
McDonald (20) performed left sympathectomy in a
woman with severe cLQTS, demonstrating not only
dramatic shortening of her QT interval but antiar-
rhythmic effects as well. We now understand that
inhibition of sympathetic tone prevents arrhythmia
triggers in patients with the arrhythmogenic sub-
strate of LQTS. It turned out that left cardiac sympa-
thetic denervation, a procedure conceived for the
wrong reasons, proved an effective therapeutic mea-
sure for LQTS patients refractory or intolerant to
FIGURE 1 Initial Reports of the Congenital Long-QT Syndrome
(A) The ﬁrst electrocardiogram of autosomal-recessive congenital long-QT syndrome (cLQTS) with deafness, published in 1957 by Jervell and
Lange-Nielsen (3), and reprinted with permission. (B) The ﬁrst publication of cLQTS without deafness by Ward (6) in 1964, reprinted with
permission. (C) Onset of spontaneous torsades de pointes in the ﬁrst patient described by Ward. Conor Ward sent us this unpublished trace in
1999 (together with the business card shown here and permission to publish), which is presented here for the ﬁrst time.
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102beta-blockers (21). Nevertheless, in those days, the
therapeutic effects of sympathectomy reinforced the
misconception of “unbalanced sympathetic in-
nervations.”
As with other familial diseases, the assumption
that a genetic etiology lies at the heart of LQTS was
held for years (22), although proper technological
methods were unavailable. Genetic research at the
end of the 1980s focused on the candidate gene
approach, which relies on physiology-based mecha-
nistic hypotheses. In 1988, calcium-channel dys-
function was proposed as possible etiology for LQTS
but was also ruled out (23). Then, in 1991, after years
of meticulous research on 3 large families with LQTS
residing in Utah, Keating et al. (24) published a
probable link between LQTS and a region in chro-
mosome 11, ultimately pointing to the Harvey-ras1 gene. Ironically, this proved to be “the wrong
gene” (25), as Harvey-ras 1 simply happened to be
near the true culprit gene, KCNQ1, which encodes the
main component of the IKs potassium channel.
Nevertheless, this formidable work shifted the
attention of scientists to genes encoding car-
diomyocyte membrane ion channels. Four years
later, 2 reports, appearing only a few pages apart in
the same issue of Cell, established HERG (26) and
SCN5A (27) (encoding a potassium and a sodium
channel, respectively) as the causes of the second
and third recognized forms of cLQTS. This ﬁnally
clariﬁed that patients with LQTS have arrhythmo-
genic prolongation of their action potential (and thus
their QT intervals) because of faulty repolarizing
currents caused by mutations in genes encoding
speciﬁc ion channels located at the myocyte
FIGURE 2 Initial Reports of Brugada Syndrome
(A) First presentation of electrocardiograms nowadays deﬁned as type I Brugada syndrome in 3 ostensibly healthy men with a pattern
“resembling myocardial infarction,” followed for years by Osher and published in 1953 (49). (B) Presentation of 6 patients with idiopathic
ventricular ﬁbrillation, including 1 with “type-I Brugada-like pattern,” by Martini et al. (50). (C) Description of 8 patients with “right bundle
branch block, persistent ST-segment elevation and sudden death” by Pedro and Josep Brugada in 1992 (48), an entity soon to become
recognized as Brugada syndrome.
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103membrane. Research on diLQTS was also inﬂuenced
dramatically by these great leaps forward.
UNDERSTANDING diLQTS. During the ﬁrst decades
after its recognition, diLQTS was considered “idio-
syncratic,” simply unpredictable, although high-risk
characteristics (older women, patients with heart
failure) had been recognized (28). In 1981 (11 years
before the discovery of the genes responsible for
cLQTS), Colatsky (29) demonstrated, in an animal
model, that quinidine prolongs the action potential,
even suggesting that suppression of the potassium
delayed-rectiﬁer current (IKr) was the probable etiol-
ogy. In 1988, Roden et al. (30) proved this hypothesis
correct, showing that action potential prolongationby quinidine was due to blockade of the IKr channel.
The same year, Jackman et al. (31) demonstrated that
patients with drug-induced TdP were at higher risk
for recurrence when exposed to a second offending
drug and that their QT intervals tended to be at the
upper end of the normal range, even before drug
exposure. This led them to propose an “inborn pre-
disposition” as the etiology for diLQTS (31). The
unraveled mechanism of cLQTS (as described earlier)
now served to establish IKr blockade as the cause of
diLQTS (32). Yet the question of who is prone to
diLQTS remained unanswered.
In 1998, Roden (33) wrote a brief editorial, “Taking
the ‘Idio’ out of ‘Idiosyncratic’: Predicting Torsades
CENTRAL ILLUSTRATION The History of Long-QT Syndrome and Brugada Syndrome Discovery
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Landmark events in the discovery of long QT syndrome and Brugada syndrome. BrS ¼ Brugada syndrome; cLQTS ¼ congenital long-QT syndrome; diLQTS ¼ drug-
induced long-QT syndrome; ICD ¼ implantable cardioverter deﬁbrillator; LQT ¼ long QT; LQTS ¼ long-QT syndrome; Na ¼ sodium.
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104de Pointes,” as a comment on a paper describing
electrocardiographic predictors of TdP after almoka-
lant treatment for atrial ﬁbrillation (34). That original
report on almokalant is no longer remembered, but a
term coined in Roden’s accompanying editorial,
“reduced repolarization reserve,” was soon to be
quoted in practically all future publications ondiLQTS. According to the principle of reduced repo-
larization reserve, some patients were more prone to
drug-induced TdP than others because of additional
factors (including genetic background) that impair
the repolarization current. Genetic support for this
model came from studies showing incomplete pene-
trance of long-QT genes among members of families
J A C C V O L . 6 7 , N O . 1 , 2 0 1 6 Havakuk and Viskin
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105carrying the mutant gene, resulting in seemingly
normal QT intervals that were unmasked only after
exposure to a repolarization challenge (35,36). The
overlap between congenital and acquired LQTS was
ﬁnally understood to some extent.
EVOLUTION OF DIAGNOSTIC PRINCIPLES AND
INTERPRETATIONS OF CHALLENGE TESTS. A direct
result of the identiﬁcation of genes causing cLQTS
was the realization that some carriers of genetic mu-
tations had QT intervals within the normal range (37),
such that a signiﬁcant overlap exists between the
QT intervals of the healthy and the affected pop-
ulations. Consequently, diagnostic tests to distin-
guish the former from the latter group became
imperative. In 1998, Yan and Antzelevitch (38)
reproduced T-wave patterns similar to the proto-
typic LQT1, LQT2, and LQT3 in a laboratory model
of canine myocardium subjected to IKs, IKr, and
sodium-channel blockers, respectively. Yet the
administration of potassium-channel blockers as a
diagnostic test for cLQTS was scarcely used in clinical
practice, because other tests, including the use of
epinephrine (39,40) and, less commonly, adenosine
(41), to expose the abnormal response of the QT in-
terval to drug-induced changes in heart rate were
used. Together with the use of exercise (42) and
“quick standing” (43) tests, this achieved excellent
diagnostic accuracy, limiting the need for drug chal-
lenge tests directly interfering with repolarization.
Use of IKr blockers to challenge repolarization was
used primarily to identify patients prone to devel-
oping diLQTS. For example, Kääb et al. (44) demon-
strated that patients with histories of drug-induced
TdP had excessive QT prolongation when challenged
with intravenous sotalol. Similarly, Kannankeril et al.
(45) showed that relatives of patients with diLQTS
had excessive QT prolongation after exposure to
quinidine. It was only in 2008 that erythromycin was
used to unmask genetically positive long-QT patients
with normal QT intervals, marking the ﬁrst use of an
IKr blocker to diagnose cLQTS (46). The use of IKr
blockers never became common practice for diag-
nosing cLQTS. This aspect of history was very
different from the sequence of events leading to the
use of sodium-channel blockers to diagnose congen-
ital BrS.
EVOLUTION OF THERAPEUTIC APPROACHES. It was
mainly through the multicenter cooperation gener-
ated by the International Long QT Syndrome Registry
(22,47), initiated by Schwartz and Moss, that
adequate data could be generated for better under-
standing of the clinical and electrocardiographic
(and ultimately genetic) risk factors for malignantarrhythmias in cLQTS. Treatment of cLQTS was never
on the basis of randomized studies. Instead, as early
as 1975, Schwartz et al. (18) reviewed all published
cases of cLQTS reported by then, including the
empirical treatment they had received. In contrast to
digoxin (proposed for its QT-shortening effect),
phenobarbital, or hydantoin, beta-blockers effec-
tively prevented recurrent arrhythmias (18). By the
time the ICD became clinically available, the medical
community knew that the vast majority of patients
with cLQTS do well on beta-blockers. It so happened
that ICD implantation became indicated only for pa-
tients with LQTS with recurrent arrhythmias while on
beta-blockers, or for a small minority of asymptom-
atic patients with identiﬁable high-risk characteristics
(2). Here, too, the evolution of therapeutic ap-
proaches in BrS was different.
ACT II: HISTORY OF BrS
BrS: DISCOVERY OF THE INHERITED FORM. In 1992,
Pedro and Josep Brugada (48) described “a distinct
clinical and electrocardiographic syndrome of right
bundle branch block, persistent ST-elevation and
sudden cardiac death” (Figure 2). Similar electrocar-
diographic patterns had been reported decades earlier
but considered benign (Figure 2A) (49). In 1989,
Martini et al. (50) described comparable ECGs in pa-
tients with otherwise “idiopathic VF” (Figure 2B) and
concluded that these patients probably had some
form of right ventricular cardiomyopathy.
Yan and Antzelevitch (51) coined the eponym
“Brugada syndrome” in a report describing the
cellular basis of the J waves on the ECG. That the
Brugada brothers were the only authors of the orig-
inal report, combined with the interesting phonetics
of “Brugada” and the long title of this newly
described entity, probably contributed to its quick
adoption. In contrast to LQTS, for which it took >30
years from its ﬁrst description to identiﬁcation of the
responsible gene, this process took only 6 years for
BrS. In 1998, Chen et al. (52) identiﬁed 3 mutations
in the SCN5A gene, encoding the alpha subunit of
the cardiac sodium channel, pointing out sodium-
channel mutations as the underlying cause of the
disease.
DRUG CHALLENGE TO UNRAVEL BrS. Soon after the
initial description of BrS, it became clear that the
distinctive coved ST-segment elevation was not pre-
sent in affected patients at all times, obviating the
need for a diagnostic test to expose “concealed BrS”
(53,54). A fascinating sequence of events set the
background for the use of sodium-channel blockers for
unraveling congenital BrS. One year before the ﬁrst
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106report of BrS (48), Krishnan and Antzelevitch (55)
demonstrated that sodium-channel blockers applied
on canine myocardium produced ST-segment eleva-
tion by abbreviating action potentials in the epicar-
dium more than in the endocardium, thus increasing
the dispersion of ventricular repolarization. Miyazaki
et al. (56) astutely noticed that 1 patient with BrS
demonstrated augmented ST-segment elevation when
treated with disopyramide (a sodium-channel blocker)
for atrial ﬁbrillation. After discussing this observation
with Antzelevitch (T. Miyazaki, personal communi-
cation, May 2015), Miyazaki challenged 3 patients with
BrS and intermittent ST-segment elevation with dis-
opyramide or procainamide (another sodium-channel
blocker). Aggravation of the Brugada electrocardio-
graphic pattern immediately occurred in all 3 patients,
and the observations were published as “Antiar-
rhythmic Drug Modulation of ST-Segment Elevation in
Patients With Brugada Syndrome” (56). Thus, when
Chen et al. (52) described that SCN5A mutations were
behind the congenital BrS, the stage was set to test
sodium-channel blockers as a means to unravel
congenital BrS. In 2000, Brugada et al. (57), by now
using ajmaline to block the sodium channel, found
100% concordance between positive results on an
ajmaline test and the presence of SCN5A mutations
in family members with BrS. Consensus papers
embraced the sodium-channel blockers drug chal-
lenge as a diagnostic criterion for congenital BrS in
proper clinical context (58).
DRUG-INDUCED BrS. Sudden deaths in cocaine users
had been reported for years, but the mechanism was
poorly understood (59,60) given the drug’s myriad
effects, including vasoactive effects, in addition to
sodium-channel-blocking activity. The ﬁrst reports
connecting cocaine use with BrS arrived in the
mid-1990s, describing coved ST-segment elevation in
young patients with normal coronary arteries, now
interpreted as “unmasked BrS” (61). Other cardiac
and noncardiac drugs were soon found to display a
similar drug-induced BrS (62).
THERAPEUTIC APPROACH FOR BrS. The ﬁrst reports
on BrS portrayed an alarming picture for asymptom-
atic patients recognized because of their ECGs.
Young, ostensibly healthy men with this peculiar
electrocardiographic pattern were considered at risk
for impending doom, as cardiac arrest rates for
initially asymptomatic patients appeared to be as
high as 10% per year (63). Given the contemporary
availability of ICDs, it seemed logical to advise such
asymptomatic patients (if they had inducible VF
during EPS) to undergo ICD implantation (64,65). As
discussed in detail (66), these recommendations werealso applied to asymptomatic patients who had their
BrS “unraveled” by sodium-channel-blocker tests.
The DEBUT (Deﬁbrillator Versus b-Blockers for Un-
explained Death in Thailand) randomized study,
conducted in the 1990s, comparing drug therapy with
ICD therapy for BrS with cardiac arrest or malignant
syncope (65), was prematurely stopped because of
the unacceptably high mortality rate in the medica-
tion arm. Regrettably, the medication used in the
“drug arm” of this trial (propranolol) was the
wrong drug to test. In fact, this beta-blocker with
sodium-channel-blocker properties is now listed
among the “drugs to preferably avoid” in BrS (62). By
the time the DEBUT trial was designed, quinidine had
already been successfully used to prevent recurrent
arrhythmias in idiopathic VF (67,68), and shortly after
publication of the DEBUT trial, quinidine was also
found to be effective in BrS (69,70). By now, however,
the ICD was already “the only acceptable therapy” for
BrS (58). As the years passed, accumulating data
showed that the rates of sudden deaths in patients
with BrS were much lower for the subgroup that was
asymptomatic at the time of diagnosis (71), and the
therapeutic approach was challenged. Nevertheless,
these patients were (and still are) referred for EPS and
may undergo ICD implantation (72).
ACT III: LOOKING BACK TO UNDERSTAND
HOW WE GOT HERE
“History never looks like history when you are
living through it.”
—John W. Gardner (73)
The therapeutic approach to asymptomatic patients
radically differs between BrS and LQTS. This is due in
part to the less forgiving course of BrS; only a mi-
nority of patients with BrS will develop arrhythmias,
but for those who do, cardiac arrest is often the pre-
senting symptom (74). In contrast, in LQTS, patients
with cardiac arrest often have warning symptoms in
the form of syncope, or identiﬁable high-risk charac-
teristics, such as a very long QT interval (75). Also, the
safety proﬁle in terms of adverse events is better for
beta-blockers than for quinidine.
However, history also appears to have inﬂuenced
the way these patients are treated. By 2006, one-half
of the ICD implantations performed in Europe for BrS
were in completely asymptomatic patients. More-
over, the most common indication for ICD implanta-
tion in the asymptomatic group was a “positive
ajmaline test with positive EPS” (76). Sure enough, at
3 years of follow-up, only 1.6% of the initially
asymptomatic patients who had type I Brugada ECGs
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107revealed by the ajmaline test had experienced spon-
taneous VF, whereas 31% had serious ICD-related
complications (76). Publication of these numbers
eventually led to a more conservative approach, and
nowadays, the proportion of ICD implantations for
asymptomatic BrS, particularly that “revealed by
drugs,” is decreasing, at least in academic institutions
(72). Prophylactic deﬁbrillator implantation for
asymptomatic patients who develop long QT in-
tervals when challenged by medications would beunthinkable to most of us. To understand how we
ended up with so many ICDs in asymptomatic pa-
tients with drug-exposed Brugada ECGs, we ought to
look back at how the understanding of LQTS and BrS
evolved over the years.
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